VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,976 | -89.5% | 428 | -86.4% | 0.00% | -100.0% |
| Q2 2023 | $66,337 | +72797.8% | 3,138 | -30.8% | 0.00% | -33.3% |
| Q1 2023 | $91 | +378.9% | 4,534 | +520.2% | 0.00% | +200.0% |
| Q4 2022 | $19 | -99.7% | 731 | +32.2% | 0.00% | – |
| Q3 2022 | $6,000 | -25.0% | 553 | -74.0% | 0.00% | – |
| Q2 2022 | $8,000 | +60.0% | 2,126 | +106.2% | 0.00% | – |
| Q1 2022 | $5,000 | +150.0% | 1,031 | +209.6% | 0.00% | – |
| Q4 2021 | $2,000 | -80.0% | 333 | -81.3% | 0.00% | – |
| Q3 2021 | $10,000 | +11.1% | 1,777 | +30.2% | 0.00% | – |
| Q2 2021 | $9,000 | +800.0% | 1,365 | +582.5% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 200 | -23.7% | 0.00% | – |
| Q2 2019 | $1,000 | -50.0% | 262 | -28.4% | 0.00% | – |
| Q1 2019 | $2,000 | -50.0% | 366 | -17.2% | 0.00% | – |
| Q4 2018 | $4,000 | +33.3% | 442 | +73.3% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 255 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | -66.7% | 255 | -45.7% | 0.00% | -100.0% |
| Q1 2018 | $9,000 | +200.0% | 470 | +136.2% | 0.00% | – |
| Q3 2017 | $3,000 | – | 199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |